|[May 19, 2014]
Research and Markets: Neurology Drug Report 2014: Profiles of 480 Active Neurology Focused Drug Development Companies
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/3h43rh/neurology_drug)
has announced the addition of the "Neurology
Drug Report 2014" report to their offering.
This report for the first time identifies and profiles 480 Active
Neurology focused Drug Development companies from 31 countries
worldwide, developing 801 neurological disorders targeting drugs. It
evaluates 16 major neurological indications drug development pipeline
and analysis it to provide thousands of active clinical trials
information; emerging drug targets, molecule types etc. Thus all
together brings the most updated and robust information at the
fingertips. It creates immense authentic knowledge-base (all information
with references) on hundreds of proprietary technologies, M&A deals and
partnering occurring in domain in last 10 years.
The 16 Major Indications detailed coverage in the report includes-
Alzheimer's Disease, Parkinson's isease, Multiple Sclerosis,
Schizophrenia, Major Depressive Disorder, Amyotrophic Lateral Sclerosis,
Ischemic and Hemorrhagic Stroke, Huntington's Disease, Epilepsy, Pain
(Migraine, Neurotropic and Post Hepatic Neuralgia), Neurological Trauma,
Anxiety Disorders, ADHD, Addiction, Autism Spectrum (News - Alert) Disorder, Bipolar
Disorder and other Rare Neurological disorder.
Report covers each individual indication Epidemiology, Treatment
options, Top selling drugs and their sales, indication Market size and
forecast with detailed drug development Pipeline Analysis covering all
Monoclonal Antibodies, Vaccines, Stem Cell Therapies, and Medical
Devices in development, it also covers promising technologies and top
drug development targets for the indication. Thus making it a versatile
Comprehensive Report for Decision-Making.
A Single Innovative and Unique Report provide Answers to Many:
It provides immense opportunities in identifying emerging cancer
companies. It covers active 272 clinical, 208 Preclinical and
Discovery stage companies along with their current partners,
technologies and cancer drug pipeline.
It provides LinkedIn (News - Alert) and E-mail IDs of all decision makers in
individual clinical companies. These thousand's of focused links helps
in saving time and linking to right person to further work on finer
16 Major Neurological Indication's Individual Drug Development
Pipeline and its Analysis, Market Size and Forecast.
Rare Neurological Indications Drug development pipelines are also
All Finer Details are further elaborated in the individual 480
Companies Profiles, all written in form of mini reports.
Offers complete and focused lead identification details for
The complete 532 Pages report is highly interlinked with all Clinical
Trials numbers and last updated status.
The Text is supplemented with 98 Tables and 36 Figures/Info-graphics.
For more information visit http://www.researchandmarkets.com/research/3h43rh/neurology_drug
[ InfoTech Spotlight's Homepage ]